Background
NMDA receptor (NMDA-R) hypofunction plays an important role in cognitive impairment in schizophrenia. NMDA-R antagonists elicit psychotic symptoms in human and schizophrenia-relevant signs in rodents, including a strong increase in cortical gamma activity. NMDA-Rs are composed of different subunits and accumulating evidence indicates that neuronal damage due to NMDA-R antagonists depends on their action on a specific type of the receptor containing the NR2A subunit. In human schizophrenics, NR2A is selectively reduced in fast firing interneurons. These neurons are critical for gamma oscillations indicating that pathological changes in gamma activity may depend on subunit-specific NMDA-R deficit. The present study tested this hypothesis.
Methods
Cortical electroencephalograms were recorded in freely moving rats and the changes in gamma power were measured after administration of NMDA-R antagonists with different subunit selectivity, including NR2A-preferring (PEAQX, n=5; NVP-AAM077, n=18), NR2B-selective (ifenprodil, n=6; threo-ifenprodil, n=4; Ro25–6985, n=13), and NR2C/D-selective (PPDA, n=8) antagonists, along with vehicle and non-selective NMDA-R antagonists (ketamine, n=10, MK801, n=12). Changes in prepulse inhibition of startle was tested after MK-801(n=6), NVP-AAM077, and Ro-6891 (n=5) injection.
Results
Strong increase in gamma power was induced by non-selective NMDA-R antagonists and by blockade of NMDA-Rs containing the NR2A subunit, with co-occurring gating deficits and diminished low frequency modulation of gamma oscillations. In contrast, selective blockade of NR2B, C, or D subunit-containing receptors had minor effects.
Conclusions
Major subtype-specific differences in the role of NMDA-Rs in cortical gamma oscillation may have implications for the pathomechanism and treatment of cognitive impairment in schizophrenia.